Although co-mutations can influence outcomes in AML patients with IDH1 R132 and IDH2 R140Q, these IDH mutations frequently appear alongside NPM1 or DNMT3A, both established indicators of a favorable prognosis. This evidence concerns the gene DNMT3A and acute myeloid leukemia.